Compare LYFT Inc (LYFT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs Merck & Co., Inc. — how do they compare? LYFT Inc trades at $17.28 (market cap $6.64B), while Merck & Co., Inc. trades at $130.13 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 48.5× LYFT Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while LYFT Inc pays none. Which is the better fit depends on your goals.
| LYFT | MRK | |
|---|---|---|
Market Cap | $6.64B | $321.77B |
Sector | Industrials | Health |
52-Week High | $24.57 | $131.84 |
52-Week Low | $12.65 | $77.60 |
Enterprise Value | $6.11B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft trades at $17.26, down 1.15% today, with strong technical momentum showing bullish moving averages but overbought RSI signals. The company demonstrates remarkable fundamental improvement with 2025 revenue reaching $6.32B and net income surging to $2.84B, achieving a 45% profit margin. Recent Q2 2026 results showed revenue growth of 16.1% with record active riders exceeding 30 million, though earnings slightly missed estimates amid higher costs.
Lyft presents a compelling turnaround story with accelerating profitability and market share gains against Uber, supported by expanding robotaxi partnerships and international growth. However, elevated valuation multiples, competitive pressures, and ongoing legal scrutiny create headwinds. With analyst consensus at $19.17 representing 11% upside potential, the stock offers growth exposure but requires monitoring of execution risks and expense management.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
